Home Online Features U.S. FDA Approves Label Expansion for ALK's ODACTRA® (House Dust Mite Allergen Tablet) for Sublingual Use as Immunotherapy to Now Include Children with House Dust Mite Allergy
U.S. FDA Approves Label Expansion for ALK’s ODACTRA® (House Dust Mite Allergen Tablet) for Sublingual Use as Immunotherapy to Now Include Children with House Dust Mite Allergy
Hand-out
Press Releases
ALK, INC.  
February 28, 2025

U.S. FDA Approves Label Expansion for ALK’s ODACTRA® (House Dust Mite Allergen Tablet) for Sublingual Use as Immunotherapy to Now Include Children with House Dust Mite Allergy

- ODACTRA is now indicated to treat house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis, in children ages 5 through 11 years, in addition to patients 12 through

avatar profile Olean Times Herald

Olean Times Herald

email Olean Times Herald

Local & Social